Director Jill C. Milne receives 528 BCRX shares as board retainer grant

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received additional company stock as part of her board compensation. On February 27, 2026, she acquired 528 shares of Common Stock at a price of $8.75 per share through a grant classified as a board retainer in stock rather than cash. After this award, she directly owns 15,382 Common Stock shares. A footnote explains the shares were issued in lieu of 100% of her prorated quarterly cash board member retainer of $4,625, meaning the company paid this portion of her board fees in stock instead of cash.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Milne Jill C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	528	$8.75	$5K

Holdings After Transaction: Common Stock — 15,382 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milne Jill C.

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		528(1)	A	$8.75	15,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625.

	/s/ Alane P. Barnes, by power of attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jill C. Milne report for BIOCRYST PHARMACEUTICALS INC (BCRX)?

Jill C. Milne reported acquiring 528 shares of BIOCRYST PHARMACEUTICALS INC Common Stock. The shares were granted as part of her board compensation, rather than purchased on the market, and reflect a standard non-cash director retainer arrangement for her board service.

On what date did Jill C. Milne receive the new BCRX shares and at what price?

Jill C. Milne received the new BCRX Common Stock shares on February 27, 2026, at $8.75 per share. This price is used for valuing the stock grant that replaced her prorated quarterly cash board member retainer of $4,625.

How many BIOCRYST (BCRX) shares does Jill C. Milne own after this Form 4 transaction?

After this transaction, Jill C. Milne directly owns 15,382 shares of BIOCRYST Common Stock. This total reflects her holdings following the award of 528 shares issued in lieu of her prorated quarterly cash board member retainer compensation.

What was the nature of the Form 4 transaction reported by Jill C. Milne for BCRX?

The transaction was a grant or award acquisition of Common Stock, coded “A” on Form 4. It represents shares issued as compensation, not an open-market buy or sell, and was recorded as part of her prorated quarterly board member retainer payment.

How does the Form 4 footnote explain Jill C. Milne’s new BCRX stock award?

The footnote states the shares were issued in lieu of 100% of her prorated quarterly cash board member retainer of $4,625. This means BIOCRYST compensated her in stock rather than paying that portion of the board fee in cash for the period.

Is Jill C. Milne’s BCRX Form 4 transaction a buy or a compensation grant?

The transaction is a compensation grant, not a market buy. It is classified as a grant, award, or other acquisition and reflects stock issued instead of a $4,625 prorated quarterly cash board member retainer for her director service.